Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seven vs fourteen days of antibiotics for uncomplicated Staphylococcus aureus bacteremia
2017-003529-13Phase 4Active
- Sponsor
- Thomas Benfield
- Start
- Sep 2017
- Modality
- Small Molecules, Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 4, randomised trial of dicloxacillin, flucloxacillin, piperacillin, tazobactam, cefuroxime and 6 more in Staphylococcal bacteremia and bacterial disease (2 arms), sponsored by Thomas Benfield. Primary endpoint: Composite primary endpoint of all-cause mortality, microbiological or clinical failure to treatment, or relapse. Started Sep 2017; status: active.
02
Drugs
03
Conditions
Staphylococcal bacteremiabacterial disease
Beyond the preview
Go deeper on 2017-003529-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003529-13.